ZIVO vs. INZY, CRDF, AARD, FHTX, AMRN, TVRD, LFCR, ZYBT, ESPR, and DBVT
Should you be buying ZIVO Bioscience stock or one of its competitors? The main competitors of ZIVO Bioscience include Inozyme Pharma (INZY), Cardiff Oncology (CRDF), Aardvark Therapeutics (AARD), Foghorn Therapeutics (FHTX), Amarin (AMRN), Cara Therapeutics (TVRD), Lifecore Biomedical (LFCR), Zhengye Biotechnology (ZYBT), Esperion Therapeutics (ESPR), and DBV Technologies (DBVT). These companies are all part of the "pharmaceutical products" industry.
ZIVO Bioscience vs. Its Competitors
ZIVO Bioscience (NASDAQ:ZIVO) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, community ranking, risk, earnings, media sentiment, institutional ownership and dividends.
In the previous week, Inozyme Pharma had 3 more articles in the media than ZIVO Bioscience. MarketBeat recorded 4 mentions for Inozyme Pharma and 1 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 1.16 beat Inozyme Pharma's score of 0.67 indicating that ZIVO Bioscience is being referred to more favorably in the media.
ZIVO Bioscience received 36 more outperform votes than Inozyme Pharma when rated by MarketBeat users. However, 82.89% of users gave Inozyme Pharma an outperform vote while only 60.74% of users gave ZIVO Bioscience an outperform vote.
ZIVO Bioscience has higher revenue and earnings than Inozyme Pharma. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Inozyme Pharma, indicating that it is currently the more affordable of the two stocks.
ZIVO Bioscience has a beta of 0.02, meaning that its share price is 98% less volatile than the S&P 500. Comparatively, Inozyme Pharma has a beta of 2.29, meaning that its share price is 129% more volatile than the S&P 500.
12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 88.3% of Inozyme Pharma shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by company insiders. Comparatively, 12.2% of Inozyme Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
ZIVO Bioscience's return on equity of 0.00% beat Inozyme Pharma's return on equity.
Inozyme Pharma has a consensus target price of $11.75, suggesting a potential upside of 194.49%. Given Inozyme Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Inozyme Pharma is more favorable than ZIVO Bioscience.
Summary
Inozyme Pharma beats ZIVO Bioscience on 10 of the 16 factors compared between the two stocks.
Get ZIVO Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ZIVO Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:ZIVO) was last updated on 6/13/2025 by MarketBeat.com Staff
